Matthew K. Robinson - 15 Jun 2022 Form 3 Insider Report for Immunome Inc. (IMNM)

Role
Chief Technology Officer
Signature
/s/ Matthew Robinson
Issuer symbol
IMNM
Transactions as of
15 Jun 2022
Net transactions value
$0
Form type
3
Filing time
21 Jun 2022, 18:00:29 UTC
Next filing
21 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMNM Stock Option (Right to Buy) 15 Jun 2022 Common Stock 5,000 $0.0600 Direct F1
holding IMNM Stock Option (Right to Buy) 15 Jun 2022 Common Stock 5,000 $0.3600 Direct F2
holding IMNM Stock Option (Right to Buy) 15 Jun 2022 Common Stock 5,000 $0.3600 Direct F3
holding IMNM Stock Option (Right to Buy) 15 Jun 2022 Common Stock 8,333 $0.5400 Direct F4
holding IMNM Stock Option (Right to Buy) 15 Jun 2022 Common Stock 43,333 $2.40 Direct F5
holding IMNM Stock Option (Right to Buy) 15 Jun 2022 Common Stock 5,000 $11.38 Direct F6
holding IMNM Stock Option (Right to Buy) 15 Jun 2022 Common Stock 14,250 $20.92 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on December 8, 2017, and one twenty-fourth (1/24th) of the remaining shares subject to the option vested every month thereafter.
F2 50% of the shares subject to the option vested on January 9, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the option vested every month thereafter.
F3 50% of the shares subject to the option vested on January 9, 2019, and one twenty-fourth (1/24th) of the remaining shares subject to the option vested every month thereafter.
F4 50% of the shares subject to the option vested on March 3, 2020, and one twenty-fourth (1/24th) of the remaining shares subject to the option vested every month thereafter.
F5 One forty-eighth (1/48th) of the shares subject to the option vested or shall vest each month commencing September 4, 2020.
F6 One forty-eighth (1/48th) of the shares subject to the option vested or shall vest each month commencing December 3, 2020.
F7 25% of the shares subject to the option vested on May 28, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest every month thereafter.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney